Meropenem Hikma (Meropenem)

Meropenem belongs to the carbapenem class and works by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final step of peptidoglycan cross‑linking, causing cell‑wall weakening, osmotic lysis, and bacterial death. Its structure provides stability against most β‑lactamases, giving it a broad spectrum of activity.

The dosage of Meropenem Hikma is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, age, and weight. Dosing regimens may range from 0.5 g to 2 g administered intravenously every 8 hours, but the exact schedule must be individualized by a qualified health professional.

Safety data for Meropenem in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Meropenem Hikma product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Meropenem offers a broad spectrum similar to other carbapenems such as imipenem‑cilastatin and ertapenem, but it has enhanced activity against certain resistant Gram‑negative organisms and better penetration into the central nervous system. Compared with non‑carbapenem β‑lactams, it is more resistant to β‑lactamase degradation, making it a preferred option for multidrug‑resistant infections when susceptibility is confirmed.

Meropenem Hikma should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Once reconstituted, the solution should be used promptly according to the manufacturer’s stability guidelines and discarded if any discoloration or particulate matter appears.

Meropenem Hikma is supplied as an intravenous solution and must be administered by slow infusion through a suitable IV line. The infusion rate is typically 15–30 minutes, but the exact rate and dilution are determined by the prescribing clinician based on patient condition and institutional protocols.

Serious adverse events include seizures, especially in patients with pre‑existing central nervous system disorders or renal impairment, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant hematologic abnormalities like neutropenia or thrombocytopenia. Prompt medical evaluation is required if any of these symptoms develop.

Meropenem Hikma is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for those with a history of seizures unless the therapeutic benefit justifies use.